About Bio Blast Pharma (NASDAQ:ORPN)
Bioblast Pharma Ltd (BioBlast) is an Israel-based development-stage biopharmaceutical company. The Company is focused on the identification, licensing, acquisition, development and commercialization of drugs for rare and ultra-rare genetic and metabolic diseases. It focuses on therapeutic platforms that offer solutions for several diseases that share a common pathophysiological mechanism, which are the functional changes that accompany a particular syndrome or disease. It also focuses on diseases with severe and debilitating manifestations. The Company has several drug candidates in clinical or preclinical development targeting neuromuscular/central nervous system (CNS) and mitochondrial diseases. Its drug candidates include Trehalose IV Solution, BB-FA (Bioblast-Friedreich's ataxia) and BBrm-02. The Company's product candidate platforms include Protein Stabilizing Platform, Read-through Platform and Mitochondrial Protein Replacement Platform.
Industry, Sector and Symbol
Industry Bio Therapeutic Drugs
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Book Value$1.12 per share
Price / Book1.93
Return on Equity-144.37%
Return on Assets-119.42%
Frequently Asked Questions for Bio Blast Pharma (NASDAQ:ORPN)
What is Bio Blast Pharma's stock symbol?
Bio Blast Pharma trades on the NASDAQ under the ticker symbol "ORPN."
When did Bio Blast Pharma's stock split? How did Bio Blast Pharma's stock split work?
Bio Blast Pharma shares reverse split on the morning of Monday, September 25th 2017. The 1-5 reverse split was announced on Monday, September 25th 2017. The number of shares owned by shareholders was adjusted after the market closes on Friday, September 22nd 2017. An investor that had 100 shares of Bio Blast Pharma stock prior to the reverse split would have 20 shares after the split.
How were Bio Blast Pharma's earnings last quarter?
Bio Blast Pharma Ltd. (NASDAQ:ORPN) announced its quarterly earnings results on Thursday, August, 25th. The biopharmaceutical company reported ($1.10) EPS for the quarter, topping the Zacks' consensus estimate of ($1.35) by $0.25. During the same period in the previous year, the company posted ($1.30) earnings per share. View Bio Blast Pharma's Earnings History.
When will Bio Blast Pharma make its next earnings announcement?
Where is Bio Blast Pharma's stock going? Where will Bio Blast Pharma's stock price be in 2017?
0 brokerages have issued 12-month price targets for Bio Blast Pharma's stock. Their predictions range from $3.15 to $3.15. On average, they anticipate Bio Blast Pharma's share price to reach $3.15 in the next twelve months. View Analyst Ratings for Bio Blast Pharma.
Who are some of Bio Blast Pharma's key competitors?
Some companies that are related to Bio Blast Pharma include Proteome Sciences plc (PRM), Biopharmx Corp (BPMX), ValiRx Plc (VAL), Ariad Pharmaceuticals (ARIA), Cynapsus Therapeutics (CYNA), Dyax Corp. (DYAX), Kythera Biopharmaceuticals (KYTH), Ocata Therapeutics (OCAT), Receptos (RCPT), Relypsa (RLYP), Tobira Development (TBRA) and ZS Pharma (ZSPH).
How do I buy Bio Blast Pharma stock?
Shares of Bio Blast Pharma can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Bio Blast Pharma's stock price today?
One share of Bio Blast Pharma stock can currently be purchased for approximately $2.16.
How big of a company is Bio Blast Pharma?
Bio Blast Pharma has a market capitalization of $7.22 million. The biopharmaceutical company earns $-16,020,000.00 in net income (profit) each year or ($2.57) on an earnings per share basis. Bio Blast Pharma employs 12 workers across the globe.
How can I contact Bio Blast Pharma?
Bio Blast Pharma's mailing address is 37 Dereh Menechem Begin St. 15th Floor, Tel Aviv L3, 6522042. The biopharmaceutical company can be reached via phone at 972-72-240-9060 or via email at [email protected]
MarketBeat Community Rating for Bio Blast Pharma (ORPN)MarketBeat's community ratings are surveys of what our community members think about Bio Blast Pharma and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Analysts' Consensus Rating for Bio Blast Pharma (NASDAQ:ORPN) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||0 Sell Ratings, 0 Hold Ratings, 0 Buy Ratings, 0 Strong Buy RatingsNo ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||$3.15 (45.83% upside)|
Consensus Price Target History for Bio Blast Pharma (NASDAQ:ORPN)
Analysts' Ratings History for Bio Blast Pharma (NASDAQ:ORPN)
(Data available from 11/24/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|4/28/2017||S&P Equity Research||Boost Price Target||$2.80 -> $3.15||Low|
|10/24/2016||Roth Capital||Set Price Target||Buy||$75.00||N/A|
|7/11/2016||Rodman & Renshaw||Reiterated Rating||Buy||N/A|
|1/28/2016||HC Wainwright||Initiated Coverage||Buy||$125.00||N/A|
|11/27/2015||Oppenheimer Holdings, Inc.||Reiterated Rating||Outperform||$160.00||N/A|
Earnings History and Estimates Chart for Bio Blast Pharma (NASDAQ:ORPN)
Earnings History by Quarter for Bio Blast Pharma (NASDAQ ORPN)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|2/23/2018|| || || || || || || || |
Earnings Estimates for Bio Blast Pharma (NASDAQ:ORPN)
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Bio Blast Pharma (NASDAQ:ORPN)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Bio Blast Pharma (NASDAQ ORPN)
No insider trades for this company have been tracked by MarketBeat.com
Latest Headlines for Bio Blast Pharma (NASDAQ ORPN)
Bio Blast Pharma (NASDAQ ORPN) Chart for Friday, November, 24, 2017